Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy

BACKGROUND: Previous proof-of-concept studies have shown that a short course of omalizumab can safely accelerate the oral immunotherapy schedule for multiple allergens simultaneously. Considering the high cost of medication, the dose-related efficacy of omalizumab at decreasing the duration of oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Langlois, Alexandra, Lavergne, Marie-Hélène, Leroux, Hélène, Killer, Kerstin, Azzano, Pauline, Paradis, Louis, Samaan, Kathryn, Lacombe-Barrios, Jonathan, Mâsse, Benoît, Des Roches, Anne, Bégin, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165401/
https://www.ncbi.nlm.nih.gov/pubmed/32328115
http://dx.doi.org/10.1186/s13223-020-00419-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165401/
https://www.ncbi.nlm.nih.gov/pubmed/32328115
http://dx.doi.org/10.1186/s13223-020-00419-z

Ejemplares similares